New Insight Into How Cells Move Copper Out of the Mitochondrial Matrix Could Guide Novel Treatments

Why It Matters

By pinpointing the export mechanism for mitochondrial copper, the study provides a molecular target for treating heart failure linked to copper dysregulation and informs safer use of copper‑based therapeutics.

Key Takeaways

• SLC25A3 identified as mitochondrial copper exporter.
• Loss of SLC25A3 traps copper, causing cardiomyocyte dysfunction.
• Elesclomol delivers copper to matrix but cannot bypass export deficiency.
• Partial rescue achieved with alternative copper‑delivery compounds.
• Findings link SLC25A3 mutations to heart failure and cuproptosis.

Pulse Analysis

Copper homeostasis is a cornerstone of cellular metabolism, especially within mitochondria where the metal fuels cytochrome c oxidase and drives ATP synthesis. When copper accumulates in the mitochondrial matrix, it triggers oxidative stress and a form of cell death known as cuproptosis. Researchers have long recognized copper’s entry pathways, but the exit route remained elusive, limiting our ability to manipulate this trace element for therapeutic gain.

The Texas A&M team leveraged elesclomol, a drug originally designed for oncology, as a molecular ferry to flood mitochondria with copper. By genetically deleting SLC25A3 in cardiomyocytes, they demonstrated that copper can enter the matrix but becomes trapped without the exporter, causing a sharp decline in oxygen consumption and cell viability. Importantly, alternative copper‑delivery compounds that bypass the matrix were able to partially restore function, highlighting that the bottleneck lies specifically at the export step rather than overall copper availability.

Clinically, mutations in SLC25A3 have been associated with dilated cardiomyopathy and other energy‑intensive disorders. Understanding that SLC25A3 mediates copper efflux opens avenues for precision medicines that either enhance its activity or provide complementary delivery routes to ensure copper reaches cytochrome c oxidase without toxic buildup. This mechanistic clarity could also refine the use of copper‑chelating agents in oncology and neurodegeneration, aligning drug design with the cell’s intrinsic metal‑transport architecture.